Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Chymase inhibition beneficial in preclinical models of atopic dermatitis

May 24, 2007

CC-10004 demonstrates activity in psoriasis

May 24, 2007

CUV-1647 begins phase III study in polymorphic light eruption

May 23, 2007

Anxiety treatment with tandospirone improves atopic dermatitis

May 23, 2007

New targeted topical cream treatment shows promise in preclinical models of psoriasis

May 23, 2007

Towards new additions to the therapeutic armamentarium in psoriasis

May 22, 2007

Novel arylhydrocarbon receptor antagonist may protect against skin photodamage

May 22, 2007

Novel VEGF inhibitor shows therapeutic potential in psoriasis mouse model

May 21, 2007

CF-101 enters clinic for third therapeutic indication

May 18, 2007

QuatRx licenses becocalcidiol to CollaGenex

May 18, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...